New drug AZD5462 tested in kidney patients for safety
NCT ID NCT06661733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how the drug AZD5462 behaves in people with reduced kidney function compared to healthy volunteers. Sixteen participants received a single oral dose, and researchers measured drug levels in the blood and monitored for side effects. The goal was to understand if kidney impairment changes how the drug is processed, which helps guide future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD5462
- What this could lead to
- If successful, this study could help determine the right dose of AZD5462 for people with kidney problems in future trials.
- What could go wrong
- This is a very early, small study (16 people) focused on drug levels and safety, not on treating any disease. Results may not apply to larger populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Sofia, 1612, Bulgaria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a damaged kidney change how antibiotics work?
- Can kidney health change how a new drug works?
- Kidney function may change how D-2570 works in the body
- Sleep drug YZJ-1139 put to the test in kidney patients
- Kidney function may change how antibiotic levornidazole acts in the body
- Kidney health may change how this drug works